# Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML

> **NCT02306291** · PHASE1,PHASE2 · COMPLETED · sponsor: **GlycoMimetics Incorporated** · enrollment: 91 (actual)

## Conditions studied

- Leukemia, Myeloid, Acute

## Interventions

- **DRUG:** GMI-1271
- **DRUG:** Mitoxantrone
- **DRUG:** Etoposide
- **DRUG:** Cytarabine
- **DRUG:** Idarubicin

## Key facts

- **NCT ID:** NCT02306291
- **Lead sponsor:** GlycoMimetics Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2017-12
- **Final completion:** 2018-05
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2019-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02306291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02306291, "Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02306291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*